In obese/overweight people, increased levels of FGF21 were evident and were correlated with triglycerides, insulin concentration, and insulin resistance [132], suggesting that FGF21 may serve as a biomarker and early indicator of MASLD severity and progression. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.